| Bioactivity | d-(RYTVELA) is a specific inhibitor of human thymocyte proliferation with an IC50 of 1 nM. d-(RYTVELA) inhibits IL-1–induced signaling pathways[1]. |
| CAS | 868844-53-5 |
| Sequence | {d-(Arg-Tyr-Thr-Val-Glu-Leu-Ala)} |
| Shortening | {d-(RYTVELA)} |
| Formula | C38H62N10O12 |
| Molar Mass | 850.96 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Tiffany Habelrih, et al. Pharmacodynamic characterization of rytvela, a novel allosteric anti-inflammatory therapeutic, to prevent preterm birth and improve fetal and neonatal outcomes. Am J Obstet Gynecol. 2023, 228, 4. |
d-(RYTVELA)
CAS: 868844-53-5 F: C38H62N10O12 W: 850.96
d-(RYTVELA) is a specific inhibitor of human thymocyte proliferation with an IC50 of 1 nM. d-(RYTVELA) inhibits IL-1–in
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.